Best printers for Home

Best Mixer Grinder

Best wired Earphones

Best 43 Inch TV in India

Best Wi Fi Routers

Best Home Theatre in India

Smart Watch under 5000

Best Laptops for Education

Best Laptop for Students

<ul class="summary-list"><li>GLP-1 medications are breakthroughs for weight loss, diabetes, and more.</li><li>Pharma companies are clamoring to produce pills or longer-lasting drugs with faster effects.</li></ul>In the race to find Ozempic 2.0, a few stand-outs are emerging.While <a target="_blank" class="" href="https://www.businessinsider.com/weight-loss-glp-1-drugs-ozempic-wegovy-mounjaro-effects-future-2023-12">GLP-1 drugs</a> have paved the way for a new era of healthcare, they have some drawbacks. They need to be injected (a draw-back for some patients), that injection must be administered once a week for effects to last, and manufacturers struggled to keep up with demand.Competition is on the way: Dozens of experimental new weight-loss medications are in development as biotech companies race to get a slice of a <a target="_blank" class="" href="https://www.businessinsider.com/economic-outlook-ozempic-economy-obesity-gdp-productivity-healthcare-novo-nordisk-2024-3">market forecast to be worth $100 billion</a>.Some are combining multiple hormones at once for enhanced effects to regulate appetite, blood sugar, and digestion. Some are trying to package these sought-after ingredients into pill form, or injectables that last longer.The next breakthrough drug may not be available until at least 2027, but the leading candidates in production give a good sense of what this market could look like in years to come."Anti-obesity medications are emerging at an astonishing pace," Dr. Christopher McGowan, a gastroenterologist and obesity medicine specialist, told Business Insider. "Forthcoming medications take the blockbuster GLP-1 medications and up the ante."<h2 id="03229fa8-bff6-4bcd-964c-60199e80d187">A new triple-action injection from Eli Lilly</h2>Why it's interesting: <a target="_blank" href="https://www.businessinsider.com/new-weight-loss-and-diabetes-drug-retatrutide-awaits-further-testing-2022-12">Retatrutide</a> is a next-gen medication that acts on three different hormones, earning it the nickname <a target="_blank" href="https://www.businessinsider.com/retatrutide-patients-lose-more-weight-than-ozempic-wegovy-mounjaro-2023-6">Triple-G.</a>That means it could lead to more weight loss than current medications like Ozempic, Wegovy, and Mounjaro, comparable to bariatric surgery.How it works: Eli Lilly's retatrutide drug is administered the same way as the market leaders Ozempic, Wegovy, Mounjaro, and Zepbound: it's a once-weekly injection.What's unique is the substance.Like semaglutide (the active ingredient in Ozempic and Wegovy), it works on GLP-1, a hormone that regulates blood sugar and appetite.Like tirzepatide (the drug in Mounjaro and Zepbound), it also works on GIP, a hormone that manages blood sugar.Uniquely, retatrutide has an additional effect, mimicking another hormone called glucagon, which may help increase the body's energy use. The idea is that it promotes weight loss by not only curbing appetite, but also burning more calories.Current research: The <a target="_blank" class="" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2301972">results of mid-stage trials</a> found that patients taking retatrutide lost an average of 58 pounds in 11 months, more and faster weight loss than has been seen with drugs currently on the market.Timeline: Retatrutide is currently being studied in <a target="_blank" class="" href="https://trials.lilly.com/en-US/trial/405675">Phase III trials</a> which are scheduled to be completed in early 2026.<h2 id="e636601d-d064-4676-851b-b8a28f3debbe">A faster-acting weight-loss drug that could be a pill or injection</h2>Why it's interesting: Early research suggests <a target="_blank" href="https://www.businessinsider.com/viking-therapeutics-weight-loss-drug-ozempic-glp-1-agonists-2024-2">VK2735</a>, from California-based Viking Therapeutics, could work faster than competitors like semaglutide and tirzepatide.How it works: VK2735 acts on both GLP-1 and GIP, similar to tirzepatide (the active ingredient in Mounjaro and Zepbound).It's being tested in pill form as well as a once-weekly injection.Current research: A <a target="_blank" class="" href="https://ir.vikingtherapeutics.com/2024-02-27-Viking-Therapeutics-Announces-Positive-Top-Line-Results-from-Phase-2-VENTURE-Trial-of-Dual-GLP-1-GIP-Receptor-Agonist-VK2735-in-Patients-with-Obesity">mid-stage trial</a> found patients on VK2735 lost an average of 14.7% of their body weight (about 32 pounds) by 13 weeks.It hasn't been directly tested against other medications but the results are comparable to what we've seen in trials of semaglutide (Ozempic, Wegovy) after 68 weeks. That suggests similar weight loss but in a fraction of the time.Timeline: Viking Therapeutics <a target="_blank" class="" href="https://ir.vikingtherapeutics.com/2024-10-23-Viking-Therapeutics-Reports-Third-Quarter-2024-Financial-Results-and-Provides-Corporate-Update">recently announced</a> it would meet with the FDA about the end of Phase II for VK2735 injections before 2025. The oral form of VK2735 is expected to enter Phase II trials by the end of this year, too.<h2 id="77bb7c6c-1d1d-424d-aa59-728b114c2d15">Eli Lilly is racing to get the first weight-loss pill on the market</h2>Why it's interesting: Eli Lilly may beat Viking Therapeutics to get the first oral GLP-1 to market.Their drug orforglipron appeals to patients who can't or don't want to use injected medications. It is also expected to be cheaper, since it's easier to produce (orforglipron isn't a <a target="_blank" class="" href="https://www.businessinsider.com/peptides-growth-hormone-hgh-new-health-fad-2023-9">peptide</a> like other GLP-1 drugs).However, the clock is ticking.Novo Nordisk already has an oral semaglutide to treat type 2 diabetes, sold under the brand name Rybelsus, and they're trialing a <a target="_blank" class="" href="https://www.businessinsider.com/ozempic-pill-semaglutide-helped-overweight-people-lose-weight-in-trial-2023-5">high-dose version of that pill that could be approved for weight loss</a>.How it works: The active ingredient in the daily pill is a small molecule which slow digestions and manages blood sugar and insulin, similar to semaglutide (Ozempic, Wegovy).Current research: <a target="_blank" class="" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2302392">Results from Phase II trials</a> found that people taking orforglipron lost between 9.4% and 14.7% of their body weight, on average, in 36 weeks.Timeline: Current <a target="_blank" class="" href="https://clinicaltrials.gov/study/NCT05869903">late-stage trials</a> are expected to last into 2027.<h2 id="1e386d6d-423a-4b83-b3c7-70231a9cd219">Novo Nordisk is touting a stronger alternative to Ozempic that may be easier to produce at scale</h2>Why it's interesting: CagriSema is a once-weekly injection that combines semaglutide (active ingredient in Ozempic and Wegovy) with a compound targeting another hormone, cagrilintide. This combination is expected to help people lose significantly more weight than semaglutide alone, Novo Nordisk says.How it works: Cagrilintide mimics the effects of a naturally-occurring hormone to regulate appetite and digestion and lower blood sugar. CagriSema adds it to the already-popular drug semaglutide, which itself helps manage hunger and blood sugar levels.Novo's chief financial officer said in an earnings call that it would source cagrilintide from a third-party company, which could help with manufacturing. Supply issues and <a target="_blank" class="" href="https://www.businessinsider.com/buy-compounded-semaglutide-online-risks-wegovy-ozempic-2023-1">shortages</a> have previously hampered its semaglutide products.Current research: One <a target="_blank" class="" href="https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)01163-7/abstract">early study</a> found patients lost more weight on CagriSema (about 15% weight loss over 32 weeks) than either semaglutide or cagrilintide alone.A Novo Nordisk executive told <a target="_blank" class="" href="https://www.reuters.com/business/healthcare-pharmaceuticals/novo-nordisk-says-its-experimental-drug-cagrisema-has-similar-side-effects-2024-11-06/">Reuters</a> that projections from the data suggest it could help people lose even more, up to 25% of their weight, over a longer timeline.Timeline: Phase III clinical trials for Cagrisema are ongoing and slated to last until late 2025. The drug could be available in 2026.<h2 id="f9e2452f-a8fe-47e5-a61d-209a3b2b28b3">A longer-lasting monthly shot from Amgen</h2>Why it's interesting: MariTide, from biotech company Amgen, could be a much longer-lasting treatment than current drugs. It only needs to be injected once a month — or even less frequently — compared to the once-weekly requirement for semaglutide and tirzepatide."Longer-acting versions of GLP-1 medications offer the potential for greater convenience and potentially improved adherence and sustained use over time," McGowan said.The catch is whether side effects might last longer, too.How it works: MariTide is similar to Mounjaro and Zepbound because it mimics GLP-1 and GIP hormones.The difference is that MariTide dials down GIP receptor activity. Amgen says this makes it easier for the body to burn fat."This is fascinating because it appears that both enhancing and opposing the GIP receptor influence weight regulation, which speaks to how little is still known about the actual weight-regulating mechanism of certain gut hormones," McGowan said.Current research: Patients in a <a target="_blank" href="https://affiliate.insider.com?h=e053792e27a615fb7dda56aa0745b0c87c4f95e380ec169abcf45f1d1b11336c&amp;postID=673380d5d057d3e5c5d03443&amp;postSlug=upcoming-glp1-weight-loss-drugs-to-watch-2024-11&amp;site=bi&amp;u=https%3A%2F%2Fwww.nature.com%2Farticles%2Fs42255-023-00966-w">small early-stage study</a> lost 14.5% of body weight on average in 12 weeks. Those who got just a single dose lost an average 8.2% of their body weight.Timeline: Data from Phase II trials is <a target="_blank" class="" href="https://www.amgen.com/newsroom/press-releases/2024/10/amgen-reports-third-quarter-2024-financial-results">expected later this year</a>, and planning is underway for Phase III trials.

5 new weight-loss drugs to watch in the fight for the next Ozempic

Inside the race to find the first antiaging drug 

The investigation into the untimely death of <keyword id="21128622" type="General" weightage="100" keywordseo="liam-payne" source="keywords">Liam Payne</keyword>, former member of One Direction, has taken a dramatic new turn as authorities make arrests and uncover additional details surrounding his tragic fall from a hotel balcony in Buenos Aires. Payne, who was just 30, was found dead on October 16 after falling from a third-floor balcony at the CasaSur Palermo Hotel. New reports now reveal the complex and troubled circumstances leading up to that fatal night. According to an official autopsy obtained by The Hollywood Reporter, Payne had multiple narcotics in his system when he died. The investigation’s spotlight has fallen on two men recently arrested: a hotel maintenance worker and a suspected local drug dealer. Both individuals are accused of supplying Payne with the narcotics, which reportedly included cocaine, as revealed by forensic tests. The investigation has also implicated an Argentine businessman who claimed to be Payne’s manager during the singer's last days. Authorities believe the businessman falsely presented himself in this role and was involved in several incidents that may have contributed to the singer's distress. <h2>Mysterious events</h2>Reports describe Payne’s hotel room as a chaotic environment: there were broken items, alcohol bottles, and narcotics. Witnesses say this tension culminated in a confrontation with two women, identified as "L" and "R," whom Payne had allegedly contacted via an escort app. In a heated encounter, the women reportedly demanded $5,000 from Payne, which led to an argument that spilled into the hotel lobby. The hotel manager attempted to de-escalate the situation by calling the Argentine businessman, who was said to be a friend of Payne. This businessman, however, now faces a charge of "abandonment of a person" for allegedly failing to notify Payne’s family about his worsening state or alerting authorities after his death. Although he has cooperated with police only through his lawyer, he has not been detained. Authorities believe that while he may not have directly caused Payne’s death, his actions could have prevented tragedy if he had intervened sooner. <h2>An expanding investigation</h2>In their search for answers, Argentine police have raided nine locations tied to those involved. They have gathered critical evidence, including nine mobile phones, computers, hard drives, and a jar of marijuana, which they believe may hold clues to what truly happened. One of the nine locations raided was the rented room of "L," who had reportedly spent time in Payne's hotel room before the fatal incident. However, after briefly speaking with authorities, she disappeared, adding another layer of mystery to the case. Neighbours reported hearing a dog barking from her now-vacant room, and police are actively searching for her. As the investigation deepens, Payne’s family is preparing for his body’s return to the UK, where they will lay him to rest. Authorities continue to analyse the extensive evidence collected in hopes of understanding the full scope of events that led to the tragic loss of the young star. (With inputs from agencies)

Mystery deepens in Liam Payne’s tragic fall: Two arrested as new clues emerge

The central government has prohibited as many as 156 <keyword id="22893276" type="General" weightage="20" keywordseo="combination-drugs" source="keywords">combination drugs</keyword> that are often administered as painkillers, multivitamins, and antibiotics, for fever and cold, among others. In a gazette notification dated August 21, the government said that the use of the drug Fixed Dose Combination of Amylase, Protease, Glucoamylase, Pectinase, Alpha Galactosidase, Lactase, Beta-Gluconase, Cellulase, Lipase, Bromelain, Xylanase, Hemicellulase, Malt diastase, Invertase, Papain is likely to involve risk to human beings whereas safer alternatives to the said drug are available. Upon recommendations of the <keyword id="20092000" type="General" weightage="20" keywordseo="Drugs-Technical-Advisory-Board" source="keywords">Drugs Technical Advisory Board</keyword>, the central government, in the greater interest of the public, has prohibited the manufacture for sale, sale, and distribution for human use of those drugs across the country with immediate effect. The move from the government comes after the matter was examined by an expert committee appointed by the central government, and the said expert committee considered the administration of this Fixed Dose Combination as "irrational". The Drugs Technical Advisory Board also examined the said FDC and recommended that "there is no therapeutic justification for the ingredients contained in this FDC. The FDC may involve risk to human beings. Hence in the larger public interest, it is necessary to prohibit the manufacture, sale or distribution of this FDC under section 26 A of the Drugs and Cosmetics Act 1940. In view of above, any kind of regulation or restriction to allow for any use in patients is not justifiable," the notification read. The list of banned drugs also includes drugs used for hair treatments, antiparasitic, skincare, anti-allergic. The medicines combined in more than one drug in a single pill are Fixed dose combination drugs FDC, these drugs are also known as cocktail drugs. The Indian Pharmaceutical Alliance supports the decision of the government. Sudarshan Jain, Secretary General, IPA told that, "this has been going for many years and there was a committee which reviewed the whole thing... This is a right step in the interest of patients and all aspects have been taken into consideration." "They have given the opportunity to give the data to support their products, so the right products will continue and when there is no data to support then companies have to withdraw it," Jain added. SEE ALSO: <a href="https://www.businessinsider.in/business/auto/webstories/2024-tvs-jupiter-vs-honda-activa-6g-which-110cc-scooter-should-you-buy/slidelist/112730069.cms">2024 TVS Jupiter vs Honda Activa 6G – which 110cc scooter should you buy?</a> <a href="https://www.businessinsider.in/tech/how-to/how-to-add-music-to-instagram-profile/articleshow/112732934.cms">You can now add music to your Instagram profile – here's how</a> <a href="https://www.businessinsider.in/business/auto/news/audi-q8-facelift-launched-in-india-with-a-1-17-crore-price-tag/slidelist/112707701.cms">Audi Q8 facelift launched in India with a ₹1.17 crore price tag</a>

India bans 156 commonly used combination drugs citing possible risks to humans

<ul class="summary-list"><li>Novo Nordisk's Saxenda helped children reduce their BMI by 5.8% in a 56-week trial.</li><li>There are no approved obesity medications for children but Saxenda is approved for teens and adults.</li></ul><a target="_blank" class="" href="https://www.businessinsider.com/novo-nordisk-cut-prices-usa-obesity-drug-wegovy-double-demand-2024-5">Danish drugmaker Novo Nordisk's</a> weight loss drug Saxenda has helped children aged six to 11 <a target="_blank" class="" href="https://www.businessinsider.com/weight-loss-glp-1-drugs-ozempic-wegovy-mounjaro-effects-future-2023-12">reduce their body mass index</a>, according to trial results released on Tuesday.The results showed that the children receiving daily injections of Saxenda were able to cut their BMI by 5.8% on average in the 56-week trial — and by 7.4% on average compared with the placebo group. BMI is a measure of fitness based on height and weight, though it's <a target="_blank" class="" href="https://www.businessinsider.com/bmi-is-bogus-best-way-to-tell-if-youre-a-healthy-weight-2016-9">widely seen as</a> an inaccurate predictor of health.There are<a target="_blank" class="" href="https://www.businessinsider.com/weight-loss-drugs-for-kids-6-years-old-mounjaro-trial-2023-10"> no FDA-approved</a> medications for children with obesity. The agency approved Saxenda, which has the chemical name liraglutide, for teenagers in 2020 and for adults in 2014. Novo will seek FDA approval for the drug for younger children, the company's head of development told the <a target="_blank" class="" href="https://www.ft.com/content/83bfafb7-72a4-455f-8def-0caa959def3d">Financial Times</a>."To date, children have had virtually no options for treating obesity. They have been told to 'try harder' with diet and exercise," said lead researcher Claudia Fox at a meeting in Madrid, where the results of the study of 82 children were presented.The medication can allow children with obesity to live healthier and more productive lives, she said.Novo Nordisk's American rival, Eli Lilly, <a target="_blank" class="" href="https://www.businessinsider.com/weight-loss-drugs-for-kids-6-years-old-mounjaro-trial-2023-10">has also been testing </a><a target="_blank" class="" href="https://www.businessinsider.com/parents-are-putting-their-kids-on-weight-loss-drugs-2023-10">obesity-beating drugs for children </a>as young as six. Novo Nordisk is the drugmaker behind the blockbuster medications Ozempic and Wegovy, while Eli Lilly produces Mounjaro and Zepbound.Wegovy and similar <a target="_blank" rel="" href="https://www.businessinsider.com/tiktok-cracks-down-on-ozempic-content-2024-4">drugs for weight loss</a> have become a huge business. The <a target="_blank" rel="" href="https://stacks.cdc.gov/view/cdc/106273">US adult obesity rate</a> was about 40% from 2017 to 2020, and <a target="_blank" href="https://www.goldmansachs.com/intelligence/pages/anti-obesity-drug-market.html">Goldman Sachs</a> researchers estimated last year that the drugs could be prescribed to 15 million Americans by 2030. The bank's researchers said the anti-obesity drug market could grow to <a target="_blank" rel=" nofollow" href="https://www.goldmansachs.com/intelligence/pages/anti-obesity-drug-market.html">$100 billion</a> by that time.The drugs' success has made Novo Nordisk the most valuable company in Europe. Its stock is up over 25% year-to-date.<h2 id="b3771b30-588f-4b4d-9231-81903e6cdd49">Childhood obesity</h2>An FDA approval on weight loss drugs for children could open up a new market for Novo Nordisk.According to the Centers for Disease Control, <a target="_blank" href="https://www.cdc.gov/obesity/php/data-research/childhood-obesity-facts.html#:~:text=Expand%20All-,Age,%25%20among%20adolescents%2012%E2%80%9319.">one in five children</a> and adolescents in the US have obesity, and the <a target="_blank" href="https://datacenter.aecf.org/data/tables/101-child-population-by-age-group#detailed/1/any/false/2545,1095,2048,574,1729,37,871,870,573,869/62,63,64,6,4693/419,420">number of children</a> ages six to 11 with obesity is about 6 million.Novo's pricing for Ozempic and Wegovy has come under recent political scrutiny. In June, US Sen. Bernie Sanders announced that Novo Nordisk CEO Lars Jørgensen would testify before the committee on September 24 at a hearing focusing on the prices that Novo Nordisk charges Americans for their drugs, Ozempic and Wegovy.Sanders has <a target="_blank" class="" href="https://www.sanders.senate.gov/wp-content/uploads/Letter-from-Sen.-Bernard-Sanders-to-Novo-Nordisk.pdf">investigated</a> the prices, saying that they are higher in the US than in other countries.The highly-coveted drugs are being <a target="_blank" rel="" href="https://www.businessinsider.com/ozempic-celebrities-denied-semaglutide-wegovy-weight-loss-drugs-khloe-kardashian-2023-3">used by celebrities,</a> including Oprah Winfrey, <a target="_blank" rel="" href="https://www.businessinsider.com/elon-musk-weight-loss-drug-wegovy-semaglutide-fit-ripped-healthy-2022-10">Elon Musk</a>, and Charles Barkley, and by <a target="_blank" class="" href="https://www.businessinsider.com/ozempic-is-killing-keto-diet-report-suggests-2024-7">non-celebrities </a>alike.

The next big market for weight-loss drugs: children 

<ul class="summary-list"><li>A woman who had life-changing results on a popular weight loss drug struggled to afford it for years.</li><li>She found stability with a cheaper version of the medication through the booming telehealth market.</li></ul><a target="_blank" class="" href="https://www.tiktok.com/@tacklingtara">Tara Rothenhoefer</a>, a 49-year-old Florida resident, says her life changed when she joined a clinical trial for a promising new weight-loss medication.Over the course of the 18-month trial, from 2020 to 2021, she <a target="_blank" class="" href="https://www.businessinsider.com/mounjaro-weight-loss-drug-not-easy-way-out-2023-10">lost more than 200 pounds</a> — more than a third of her body weight. Suddenly, she didn't have pervasive "<a target="_blank" class="" href="https://www.businessinsider.com/weight-loss-drug-semaglutide-helping-dispel-harmful-stereotypes-patients-say-2022-12">food noise</a>" or preoccupation with eating that had bothered her for years, allowing her to freely pursue healthy habits.Rothenhoefer had been testing a drug, sold by pharmaceutical company Eli Lilly, which later won FDA approval for weight loss in 2023 under the brand name <a target="_blank" class="" href="https://businessinsider.com/eli-lilly-mounjaro-zepbound-approved-weight-loss-stronger-than-wegovy-2023-11">Zepbound</a>. A similar version of this drug, called Mounjaro, has been available to people with type 2 diabetes since 2022.But when the trial ended, she was faced with the prospect of paying over $1,000 per month to continue this drug, or try to keep the weight off unmedicated — an incredibly tricky feat since the drug's effects are not long-lasting, as far as we know.Now, after three years of navigating a nightmarish maze of shortages and lack of insurance coverage, she finally has steady, affordable access to her medication.She's not only one.The high price of weight-loss medication has left out millions of Americans who could benefit, as highlighted in recent <a target="_blank" class="" href="https://markets.businessinsider.com/news/stocks/novo-nordisk-ceo-faces-senate-questions-over-high-prices-of-ozempic-and-wegovy-in-us-1033798280">Senate Committee Hearings</a>, where Novo Nordisk's CEO faced tough questions about its versions of similar drugs, Ozempic and Wegovy.Here's how she, like many others, has found a way around the snarls of the healthcare system to stay on the drug.<h2 id="b6ae44a3-53cb-4a2c-8ff1-f68263c11f64">At first, she tried the pharma solution: coupons</h2>After the trial ended, Rothenhoefer's doctor issued her a prescription for Mounjaro but she knew she couldn't afford it with her office job.Not a problem, manufacturer Eli Lilly told her — she could get a coupon, allowing her to access the drug at a steep discount.Providing coupons is a common practice for drug makers to incentivize patients to try their product, instead of a competitor's, especially when it's a new offering in an already-hot and high-priced market.However, the coupon expired in June 2023. And all she could do was ration out her remaining doses and hope for the best."My insurance doesn't cover it. Most people can't afford it. I had no choice," she said.<h2 id="9f175e6c-deef-4bd9-8285-ccf7d1bc03be">Spreading out doses to try to make the drug last longer</h2>Rothenhoefer did what she could to make her supply of medication last, and tried to dose every 10 to 14 days instead of weekly, but the scale began creeping back up regardless of what she did."I was having a lot of fluctuations in weight even though my habits were the same," she said.Research suggests that people who lose weight on GLP-1 medications need to continue taking them or they'll <a target="_blank" class="" href="https://www.businessinsider.com/zepbound-weight-gain-stop-taking-tirzepatide-2023-12">regain the weight</a> so Rothenhoefer needed a long-term plan just to keep her weight stable."I'm in maintenance, which I'll be in for the rest of my life," she said.But she's since been able to find a steady, affordable supply, and now takes a dose of 7.5 - 10 mg of compounded tirzepatide weekly, delivered to her door, and plans to stay this course for at least the next year, if not longer.<h2 id="86a425c0-21ca-447d-a94f-5bc79360d4e5">The promise of cheaper 'compounded drugs'</h2>Rothenhoefer said she had heard about a cheaper version of the GLP-1s known as compounded tirzepatide.The active ingredient in Mounjaro and Zepbound is tirzepatide, one type of <a target="_blank" class="" href="https://www.businessinsider.com/weight-loss-glp-1-drugs-ozempic-wegovy-mounjaro-effects-future-2023-12">GLP-1 drugs</a>, which mimic hormones that our bodies naturally produce to control appetite and blood sugar. (Ozempic and Wegovy contain a similar drug called <a target="_blank" class="" href="https://www.businessinsider.com/how-weight-loss-meds-injections-compare-costs-results-side-effects">semaglutide</a>.)<a target="_blank" class="" href="https://www.businessinsider.com/buy-compounded-semaglutide-online-risks-wegovy-ozempic-2023-1">Compounded medications</a> are custom formulations of drugs provide by specialized pharmacies. Since brand name GLP-1 drugs have long been in shortage, drug compounders are legally allowed to fill the gap in demand with their own versions of the same active ingredients, semaglutide or tirzepatide.While regulated, these compounded drugs aren't FDA-approved, raising concerns from doctors about variations in quality.The grey market of weight-loss drugs is vast and complicated.Some weight-loss clinics or med spas offer injections for as little as $20, with way of vetting what you're getting, and some online clinics are simply money scams, a <a target="_blank" class="" href="https://www.businessinsider.com/scientist-cheaper-ozempic-sold-online-contains-dangerous-ingredients-2024-8">recent study found</a>.Rothenhoefer contacted a telehealth company with a verified, credentialed compounding pharmacy.The price for her dose of the compounded version is $329 monthly, compared to the brand name's list price of more than $1,000 per month.Pharmaceutical companies are pushing back against their low-cost competitors in the GLP-1 market.In August, Eli Lilly halved the price of its <a target="_blank" class="" href="https://www.businessinsider.com/eli-lilly-cut-price-zepbound-tirzepatide-weight-loss-drug-copycats-2024-8">weight-loss drug Zepbound </a>through single-dose vials — a bid to lure customers back to brand-name drugs, analysts said.But Rothenhoefer said that if manufacturers want people to buy their products, prices need to keep dropping."I think everyone would be on the branded if it were accessible and affordable. But there are people out there that are alive now that might not have been or might have been in five years if they didn't get their health under control," she said of patients like her who are now using compounded medications.<h2 id="bc1e401f-b010-4062-a1c7-ffc442cacc15">A huge relief</h2>Previously, Rothenhoefer said she was constantly worried about protecting the dwindling stockpile of medication in her refrigerator.Now, with reliable access, a huge burden has been lifted, Rothenhoefer said. She is no longer fixated on rushing to get ice in a cooler for her meds as a first priority, and is free to think about everything else that matters."I don't have any fear at all anymore," she said. "My mind has been totally put at ease and I can now focus on the rest of my life."

Weight-loss drugs are life-changing — and expensive. Here's one woman's solution.

<keyword id="19894886" type="General" weightage="20" keywordseo="china" source="keywords">China</keyword>'s top drug regulator has cleared a mpox vaccine developed by local drug firm Sinopharm for clinical trials which could be the country's first experimental dose to battle the deadly disease. The domestic vaccine candidate, created by the Shanghai Institute of Biological Products and administered by Sinopharm, is expected to play an important role in preventing and controlling mpox infections, the company said in a statement released on Monday afternoon. There is currently no approved mpox vaccine in China. Globally, a few vaccines have been approved in the United States, Canada, the European Union, Japan and Russia. In China, a vaccine candidate typically goes through three phases of clinical trials before gaining market approval. The process can take years, even decades. However, the National Medical Products Administration, China's top drug regulator, has launched a number of accelerated or streamlined channels to facilitate applications of novel drugs and vaccines or those in urgent need, state-run China Daily reported on Tuesday. According to the company, the new vaccine is a replication-deficient vaccine based on a strain called MVA. The description is the same as <keyword id="22925756" type="General" weightage="20" keywordseo="jynneos" source="keywords">Jynneos</keyword>, the world's first mpox vaccine approved by the <keyword id="20256595" type="General" weightage="20" keywordseo="food-and-drug-administration" source="keywords">Food and Drug Administration</keyword> in the United States in 2019. The <keyword id="19902256" type="General" weightage="20" keywordseo="world-health-organisation" source="keywords">World Health Organisation</keyword> said on August 14 that the mpox outbreak in <keyword id="19924003" type="General" weightage="20" keywordseo="africa" source="keywords">Africa</keyword> constitutes a public health emergency of international concern - its highest form of alert. Previously, in July 2022, the WHO declared a global emergency but then lifted it in May last year because of a sustained decline in international cases. So far, more than 120 countries and regions across the world have reported more than 100,000 confirmed infections and 226 related deaths. China reported its first imported case in September 2022 and the first domestic case in June last year. By the end of July, the nation had reported 2,567 confirmed cases, according to the China Daily report. SEE ALSO: <a href="https://www.businessinsider.in/business/auto/news/ather-energy-looks-to-raise-3100-crore-files-ipo-papers-with-sebi/articleshow/113214971.cms">Ather Energy looks to raise ₹3,100 crore, files IPO papers with SEBI</a> <a href="https://www.businessinsider.in/tech/mobile/news/iphone-16-pro-iphone-16-pro-max-india-price-specifications/articleshow/113204340.cms">iPhone 16 Pro and iPhone 16 Pro Max with bigger displays, A18 Pro chipset launched starting at ₹1,19,900</a> <a href="https://www.businessinsider.in/tech/mobile/news/apple-iphone-16-iphone-16-plus-price-specs/articleshow/113203568.cms">iPhone 16, iPhone 16 Plus with A18 chipset launched starting at ₹79,900</a>

You Searched For "Drugs" and got 7 results

5 new weight-loss drugs to watch in the fight for the next Ozempic

Gabby Landsverk

Inside the race to find the first antiaging drug

Insider

Mystery deepens in Liam Payne’s tragic fall: Two arrested as new clues emerge

BI India Bureau

India bans 156 commonly used combination drugs citing possible risks to humans

ANI

The next big market for weight-loss drugs: children

Shubhangi Goel

Weight-loss drugs are life-changing — and expensive. Here's one woman's solution.

Gabby Landsverk

China's drug regulator clears mpox vaccine; to undergo clinical trial

PTI

Popular Keywords

Buying Guides